Approach Considerations

Medical care

The most important tools in treatment of mixed connective tissue disease (MCTD) include tailoring the medical regimen, promptly attending to disease flare, and performing careful and frequent clinical and laboratory evaluations to test for new disease manifestations.

Some patients have physical findings and laboratory studies that more closely resemble lupus (particularly double-stranded DNA and hypocomplementemia), and treatment should be tailored to treat a lupuslike disease.

Strongly consider annual echocardiography, pulmonary function testing, and barium swallow.

Surgical care

No specific surgical care is required.

Consultations

A rheumatologist should be an integral part of the medical care team supporting the patient with mixed connective tissue disease. Other consultants depend on the organ systems involved and the disease severity.

Diet

Diet restrictions are driven by medical therapy and disease manifestations. Prescribe a low-fat, calcium-sufficient diet with no added salt for patients receiving corticosteroids.

Recognize and evaluate nontraditional remedies along with traditional medications for safety and efficacy.

Activity

Encourage the patient with mixed connective tissue disease to maintain a healthy lifestyle. Limitations should occur only secondary to serious organ involvement that prevents performance of activities.

Advise patients with mixed connective tissue disease to avoid fatigue.

Advise patients with mixed connective tissue disease to avoid significant cold exposures or to dress accordingly to decrease Raynaud symptoms.

Medication

Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972 Feb. 52(2):148-59. [Medline].
Alarcon-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam, The Netherlands: Elsevier; 1987. 33-40.
Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam, The Netherlands: Elsevier; 1987. 41-7.
Mairesse N, Kahn MF, Appelboom T. Antibodies to the constitutive 73-kd heat shock protein: a new marker of mixed connective tissue disease?. Am J Med. 1993 Dec. 95(6):595-600. [Medline].
Nowicka-Sauer K, Czuszynska Z, Majkowicz M, et al. Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus. Lupus. 2012 Aug. 21 (9):927-33. [Medline].
Berard RA, Laxer RM. Pediatric Mixed Connective Tissue Disease. Curr Rheumatol Rep. 2016 May. 18 (5):28. [Medline].
Tarvin SE, O'Neil KM. Systemic Lupus Erythematosus, Sjögren Syndrome, and Mixed Connective Tissue Disease in Children and Adolescents. Pediatr Clin North Am. 2018 Aug. 65 (4):711-737. [Medline].
Sharp G. The origin of mixed connective tissue disease: a stimulus for autoimmune disease research. Lupus. 2009. 18(12):1031-2. [Medline].
Michels H. Course of mixed connective tissue disease in children. Ann Med. 1997 Oct. 29(5):359-64. [Medline].
Tsai YY, Yang YH, Yu HH, Wang LC, Lee JH, Chiang BL. Fifteen-year experience of pediatric-onset mixed connective tissue disease. Clin Rheumatol. 2010 Jan. 29 (1):53-8. [Medline].
Witczak BN, Hetlevik SO, Sanner H, et al. Effect on cardiac function of longstanding juvenile-onset mixed connective tissue disease: a controlled study. J Rheumatol. 2019 Jul. 46 (7):739-47. [Medline].
Knight A, Weiss P, Morales K, Gerdes M, Gutstein A, Vickery M, et al. Depression and anxiety and their association with healthcare utilization in pediatric lupus and mixed connective tissue disease patients: a cross-sectional study. Pediatr Rheumatol Online J. 2014. 12:42. [Medline]. [Full Text].
Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: An overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012 Feb. 26(1):61-72. [Medline].
Tanaka Y, Kuwana M, Fujii T, et al. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol. 2021 Jan. 31 (1):29-33. [Medline]. [Full Text].
Malleson PN, Mackinnon MJ, Sailer-Hoeck M, Spencer CH. Review for the generalist: The antinuclear antibody test in children - When to use it and what to do with a positive titer. Pediatr Rheumatol Online J. 2010 Oct 20. 8:27. [Medline]. [Full Text].
Hetlevik SO, Flatø B, Aaløkken TM, et al. Pulmonary Manifestations and Progression of Lung Disease in Juvenile-onset Mixed Connective Tissue Disease. J Rheumatol. 2019 Jan. 46 (1):93-100. [Medline].
Ingegnoli F, Zeni S, Gerloni V, Fantini F. Capillaroscopic observations in childhood rheumatic diseases and healthy controls. Clin Exp Rheumatol. 2005 Nov-Dec. 23(6):905-11. [Medline].
Hughes M, Moore T, O'Leary N, Tracey A, Ennis H, Dinsdale G, et al. A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders. Rheumatology (Oxford). 2015 Aug. 54 (8):1435-42. [Medline].
Pizzorni C, Giampetruzzi AR, Mondino C, Facchiano A, Abeni D, Paolino S, et al. Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis. Microvasc Res. 2017 May. 111:20-24. [Medline].
Biro E, Szekanecz Z, Czirjak L, et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol. 2006 Mar. 25(2):240-5. [Medline].
Bodolay E, Szekanecz Z, Devenyi K, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005 May. 44(5):656-61. [Medline].
Ito S, Nakamura T, Kurosawa R, Miyamae T, Imagawa T, Mori M. Glomerulonephritis in children with mixed connective tissue disease. Clin Nephrol. 2006 Sep. 66(3):160-5. [Medline].
Mier R, Ansell B, Hall MA, et al. Long term follow-up of children with mixed connective tissue disease. Lupus. 1996 Jun. 5(3):221-6. [Medline].
Mier RJ, Shishov M, Higgins GC, et al. Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am. 2005 Aug. 31(3):483-96, vii. [Medline].
Mier RJ, Shishov M, Higgins GC, Rennebohm RM, Wortmann DW, Jerath R. Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am. 2005 Aug. 31(3):483-96, vii. [Medline].
Singsen BH, Bernstein BH, Kornreich HK, et al. Mixed connective tissue disease in childhood. A clinical and serologic survey. J Pediatr. 1977 Jun. 90(6):893-900. [Medline].
Tiddens HA, van der Net JJ, de Graeff-Meeder ER, et al. Juvenile-onset mixed connective tissue disease: longitudinal follow-up. J Pediatr. 1993 Feb. 122(2):191-7. [Medline].